🇺🇸 FDA
Pipeline program

remicade (anti tumor necrosis factor inhibitor)

1312-079-541

Phase 2 small_molecule active

Quick answer

remicade (anti tumor necrosis factor inhibitor) for Takayasu's Arteritis is a Phase 2 program (small_molecule) at Hospital Authority, Hong Kong with 1 ClinicalTrials.gov record(s).

Program details

Company
Hospital Authority, Hong Kong
Indication
Takayasu's Arteritis
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials